CAMKK2 and neoplasm: Importantly, genetic ablation of CaMKK2, or its pharmacological inhibition led to accumulation of less immune-suppressive myeloid cells and more activated CD8+ T cells in the tumor microenvironment, which results in tumor growth inhibition.